Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Autor: Butterfield, Russell, Connolly, Anne, Muntoni, Francesco, Joyce, Nanette C., Evans, Maya, Abedi, Mehrdad, Surampudi, Prasanth, Jhawar, Sanjay, Dayan, Jonathan G., Anthonisen, Colleen, Goude, Erica, Nicorici, Alina, Sarwary, Omaid, Prasad, Poonam, Baek, Jayoon, Newton, Andrew, Johnson, Hannah, Kusmik, Kyle, Filar, Lauri, Edmondson, Angie, Rybalsky, Irina, Chouteau, Wendy, Giordano, Anthony F., Rodriguez, Aixa, Anderson, Kristan, Wezel, Germaine, Vega, Melisa, Duke, Julie, Collado, Jorge, Civitello, Matthew, Wells, Julie, Pyzik, Erika, Rehborg, Rebecca, Brown, Michelle, Van Eyk, Jennifer, Rogers, Russell G., McDonald, Craig M ^*, Marbán, Eduardo, Hendrix, Suzanne, Hogan, Nathaniel, Ruckdeschel Smith, Rachel, Eagle, Michelle, Finkel, Richard S, Tian, Cuixia, Janas, Joanne, Harmelink, Matthew M, Varadhachary, Arun S, Taylor, Michael D, Hor, Kan N, Mayer, Oscar H, Henricson, Erik K, Furlong, Pat, Ascheim, Deborah D, Rogy, Siegfried, Williams, Paula, Marbán, Linda

Publikováno v: In The Lancet 12-18 March 2022 399(10329):1049-1058